This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
3 Stocks to Buy Now for Growth & Dividends to Counter Low Bond Yields
by Benjamin Rains
Investors might want to consider buying stocks that also provide income via dividends given the current interest rate environment...
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $90.50 in the latest trading session, marking a +0.89% move from the prior day.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - September 14, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
The Extreme Risks of Trading Your Own Retirement Assets - September 14, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Pharma Stock Roundup: AZN & PFE's Coronavirus Vaccine Updates & FDA Approvals
by Kinjel Shah
AstraZeneca (AZN) halts coronavirus vaccine study. FDA approves Roche (RHHBY) and Glaxo's (GSK) medicines.
The Zacks Analyst Blog Highlights: Alphabet, UnitedHealth, AbbVie, Adobe Systems and Anheuser-Busch
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, UnitedHealth, AbbVie, Adobe Systems and Anheuser-Busch
Zacks Market Edge Highlights: MRK, ABBV, PXD, VBR and VIOO
by Zacks Equity Research
Zacks Market Edge Highlights: MRK, ABBV, PXD, VBR and VIOO
Generation X Investors: Deja Vu?
by Tracey Ryniec
Generation X investors came of age in the dot-com boom when Microsoft and other tech titans hit new highs. Now, in 2020, it's happening again.
Simple Secrets Anyone Can Use to Reach Early Retirement - September 09, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Top Stock Reports for Alphabet, UnitedHealth & AbbVie
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), UnitedHealth Group (UNH) and AbbVie (ABBV).
Novartis (NVS) Releases Positive Data on Enerzair Breezhaler
by Zacks Equity Research
Novartis (NVS) posts favorable data on asthma treatment Enerzair Breezhaler at the ERS International Congress 2020.
AbbVie Partners With Chinese Biotech for Cancer Candidate
by Zacks Equity Research
AbbVie (ABBV) signs a collaboration agreement with China's I-Mab for developing/commercializing the latter's lemzoparlimab to address various cancer types.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - September 07, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
The Extreme Risks of Trading Your Own Retirement Assets - September 04, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Arena (ARNA) Starts Phase II Alopecia Areata Study on Etrasimod
by Zacks Equity Research
Arena (ARNA) doses first patients in a phase II study evaluating etrasimod in patients with alopecia areata.
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
3 Top Dividend Stocks to Maximize Your Retirement Income - August 31, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Powerful Proof Anyone Can Invest for an Early Retirement - August 31, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Novartis Announces Positive Data on PNH & Cholesterol Drugs
by Zacks Equity Research
Novartis (NVS) announces new positive data on its PNH drug, LNP023, and an investigational cholesterol-lowering treatment, inclisiran.
Pharma Stock Roundup: AZN's Coronavirus Antibody Combo Study, & Other Updates
by Kinjel Shah
AstraZeneca (AZN) begins dosing in phase I study on antibody cocktail therapy to treat COVID-19. Glaxo's (GSK) Blenrep gets approval in Europe.
AbbVie (ABBV) Down 2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Extreme Risks of Trading Your Own Retirement Assets - August 27, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Novartis' (NVS) Leukemia Drug Meets Goal in Late-Stage Study
by Zacks Equity Research
Novartis' (NVS) chronic myeloid leukemia candidate meets primary endpoint in a phase III study.
AbbVie Seeks FDA Approval for Rinvoq in Ankylosing Spondylitis
by Zacks Equity Research
AbbVie (ABBV) files an application to the FDA, seeking its nod for a new indication of Rinvoq, which is active ankylosing spondylitis. The drug is already marketed to treat rheumatoid arthritis.
Teva Stock Down on Charges of Illegal Generic Price Fixing
by Zacks Equity Research
Teva (TEVA) has been indicted on charges of conspiring with other generic drugmakers to raise prices for generic drugs.